Tīmeklis2024. gada 1. sept. · Total neoadjuvant therapy for rectal cancer: making sense of the results from the RAPIDO and PRODIGE 23 trials. Cancer Treat Rev (2024) R Glynne-Jones Interpreting the RAPIDO trial: factors to consider. Lancet Oncol (2024) FA Calvo et al. Intraoperative radiation therapy part 2. Clinical results. Tīmeklis2024. gada 21. marts · However, neither RAPIDO nor PRODIGE-23 impacted favourably on local control, allowed more sphincter sparing/less stomas or improved overall survival. The lack of evidence that TNT improves overall survival (OS) should be weighed against the fact that that neither trial was adequately powered to capture …
Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: …
Tīmeklis2024. gada 18. dec. · Recently, two large, randomised phase III clinical trials of total neoadjuvant therapy (TNT) in locally advanced rectal cancer were published (RAPIDO and PRODIGE 23). These two trials compared short-course radiotherapy (SCRT) followed by chemotherapy with standard chemoradiotherapy (CRT) and … TīmeklisThe UNICANCER-PRODIGE 23 trial is a multicentre, open-label, phase 3, randomised, controlled trial done at 35 French hospitals (comprehensive cancer centres, … confined space training southampton
Comparison of the outcomes of the RAPIDO [13] and PRODIGE 23 …
TīmeklisI read with interest the Article by Renu Bahadoer and colleagues1 in The Lancet Oncology, which reported results of the phase 3 RAPIDO trial in locally advanced rectal cancer. I applaud the authors' work and agree with their conclusion, but I have concerns regarding the use of the RAPIDO protocol for patients with stage cT4 low rectal … TīmeklisThe significantly improved disease-free survival in the neoadjuvant chemotherapy group and the decreased neurotoxicity indicates that the perioperative approach is … Tīmeklis2024. gada 8. janv. · The 3-year disease-free survival, distant metastasis–free survival, and pathologic complete response rate were statistically improved in the mFOLFIRINOX therapy arm (Table). 14 These results, of observed pathologic complete response of about 28% in the RAPIDO and PRODIGE 23 trials, beg the next study, which is … confined space training sydney